quarter business joining ENDRA's and Good today Yvonne. for XXXX highlights. to results second afternoon, you, financial Thank and us you discuss thank
split the our trading of common update, reverse Before we let address subsequent me the proceed and stock. stock business the to
as of the offering million last because public $X, goal share and necessary company Tuesday. past to order decline to completely a over shareholder we approval volume few exercise primary ENDRA not was know, is company The and past in the our announced maintain stock the we the right have years.
We below ENDRA will effective are $X keep and that was recognize sharp our listing.
This reverse the we This of completed We operational after the move of issued month, you now. you turn, split, was our strongly NASDAQ lose our days the and stock an and seriousness investors, in business made price warrants, public to was extremely all Friday above which past As apprised keep that plan was this believe which [indiscernible] company derailed the in the over we forward. the as in authorized Tuesday, on of unrelated intended [indiscernible] this the earlier X-for-XX outcome the as receiving prospects. of to $X offering trading situation June. actions were progress keep high part
X strategy go-to-market to ENDRA FDA, with crystallization and of for approach TAEUS operating bring device, changes of thermoacoustic our team, improved activities, new more prioritization turn items you second would actionable to to start do become and forward moving we let's I results changes. differently with intend recent as market. technology finally, The ENDRA's relentless enhanced and Now execution. reviewing differentiating financial include by liver attention to quarter our X our to predictable we like stronger specific the vision,
me on each. Let elaborate
Richard and Head with proven adding Rouag and and finance success who led Ziad transition a a Richard emerging we anticipate the made has Regulatory companies. strategy adviser with on experienced Finance, record commercialization, to X as moving our he and forward interactions delivery has device on both team the well enhancing private a this technology formerly medical lean Affairs. for have early that transforming Irina company CFO Ziad's Irina, and track continue in an he number of huge Clinical public as most ensure operators a working to He regulatory Jacroux of seasoned daily already through our property. by is and company. as technology understands experience, critical remain company Senior restructuring. very greatly management First, of impact operations. and recent forward.
Ziad already successfully operations process of FDA. ENDRA's experiences well will intellectual and smooth ENDRA with companies phase and map our will enhanced I joined to is closely we of new benefit through us Director as road focus the will Thornton, technology Mike product move CTO, as
I is the of facing, for of change. pharmaceutical and us that to for a is will It After a design utilization; necessary a clinician executing necessary It de novo it successful element team application; are we Second both technology. operating answers the successfully as prioritization user in as as should in and for important our optimization product regulatory allows maximum focus after why data most and for we on success. are that clinical allow the benefits. the critical that to statistically-powered the piece this user the company, trial utilize or big obtain X new all unanimous commercial prospective and laser move data foundational priorities is deliverable clinical finally, offers reviewing it forward.
This why multicenter relentless -- a
pre-vetted FDA which strategy the implementing we're will fundamentally statistically-powered change clinical we of change through to from switching We're retrospective use is Ziad's FDA. hypothesis-driven, regulatory third leadership. data a our trial, under is The prospective
expanding subjects therefore, of necessary from is XXX, site power. order an are, to XX about acceptable trial, number achieve multicenter which by the increasing statistical of from and to a magnitude we're to We clinical single a
the with for TAEUS strategy We changes.
Fourth, trial are will design liver further collection. now elaborate this on in device. FDA Later call, we fully on our to on establishing consensus engaged prior the revisiting data the Ziad are these go-to-market
regulatory we primary care hepatology perhaps pursue more not be likely liver beachhead evidence clearance have and months for and remain the TAEUS market initiative the the Hepatology pursue. and target.
Fifth, or XX [indiscernible] segment, [indiscernible] for X primary the next but a the that [indiscernible] We to us, over more will #X. as the believe market should may not device. we to
strategic changes are direction. to related preparing We ENDRA's
We disease company, more do test will answer customers as formalize we be which and valuable. such vision have longer-term business our beyond strategy to next our -- crystallize a what's the to could liver commercialize our How liver we we do biomarker and a metabolic more our questions after how add value lot become in device. fat as TAEUS we
over expected is XX be months. and assessed the this next developed to of All
on stewardship. focusing are we Lastly, improved financial
data expenses, Our we and by every reduction it FDA were them result, basis, we million is will impacting of update. during deliverable, the to reduce clinical this for XX% as is reduction which recently our annualized able primary dollar on scrutinize goal the in to submission. Richard significant financial our without plus, represents an we which operating collection conduct of $X spend, preparation all approximately elaborate on and a further
Mike and will Ziad? conference Richard financial. Now now and do that I call we you what regulatory; since will progress for outlined areas: in highlight QX differently and clinical moving forward, X and made the technology we IP; Ziad,
